87600-97-3

Basic information

• Product Name: 5-Pyrimidinecarbonyl chloride, 4,6-dichloro- (9CI)
• Synonyms: 5-Pyrimidinecarbonyl chloride, 4,6-dichloro- (9CI);5-PyriMidinecarbonyl chloride, 4,6-dichloro-;4,6-Dichloropyrimidine-5-carbonyl chloride
• CAS NO: 87600-97-3
• Molecular Formula: C₅HCl₃N₂O
• Molecular Weight: 211.43324
• Product Categories: ACIDHALIDE
• Mol File: 87600-97-3.mol
• Article Data: 19

Chemical Properties

• Melting Point: 30-32 °C(Solv: ligroine (8032-32-4))
• Boiling Point: 303.1°C at 760 mmHg
• Flash Point: 137.1°C
• Appearance: /
• Density: 1.675g/cm³
• Vapor Pressure: 0.00095mmHg at 25°C
• Refractive Index: 1.588
• PKA: -6.54±0.26(Predicted)
• CAS DataBase Reference: 5-Pyrimidinecarbonyl chloride, 4,6-dichloro- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Pyrimidinecarbonyl chloride, 4,6-dichloro- (9CI)(87600-97-3)
• EPA Substance Registry System: 5-Pyrimidinecarbonyl chloride, 4,6-dichloro- (9CI)(87600-97-3)

Safety Data

• Hazardous Substances Data: 87600-97-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C5HCl3N2O/c6-3-2(5(8)11)4(7)10-1-9-3/h1H

Upstream product

• 87600-98-4 4,6-dichloro-pyrimidine-5-carboxylic acid 
• 5305-40-8 2,6-dichloro-pyrimidine carbaldehyde 

Downstream Products

• 285991-63-1 4,6-dichloro-pyrimidine-5-carboxylic acid (2-phenylethynyl-phenyl)-amide 

Relevant articles and documents

CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO

The invention relates to inhibitors of calcium-dependent protein kinase 1 (CDPK1) and pharmaceutical preparations thereof. The invention further relates to methods of treatment of parasitic infections, such as T. gondii, P. falciparum, C. hominis, or C. parvum infections, using the novel inhibitors of the invention.

HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSTION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to a heteroaryl derivative or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition for preventing or treating diseases associated with PI3 kinases, containing the same as an active ingredient. The heteroaryl derivative according to the present invention has an excellent effect of selectively inhibiting PI3 kinases, thereby being useful in preventing or treating PI3 kinase diseases such as: cancers, autoimmune diseases, and respiratory diseases.

SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE

The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans.